Advertisement
Research Article| Volume 20, ISSUE 3, P591-602, September 2000

IGF-I and Osteoporosis

  • Clifford J. Rosen
    Correspondence
    Address reprint requests to Clifford J. Rosen, MD, Maine Center for Osteoporosis Research and Education, St. Joseph Hospital, 360 Broadway, Bangor, ME 04401.
    Affiliations
    From the Maine Center for Osteoporosis Research and Education, St. Joseph Hospital, Bangor, Maine
    Search for articles by this author
DOI:https://doi.org/10.1016/S0272-2712(18)30055-6
IGF-I and Osteoporosis
Previous ArticleCalcium and Vitamin D: Diagnostics and Therapeutics
Next ArticleThe Treatment of Osteoporosis: Antiresorptive Therapy
      This paper is only available as a PDF. To read, Please Download here.
      This article discusses the clinical use of insulin-like growth factors (IGF) as a potential diagnostic tool for osteoporosis. Although there is a numerical relationship between measurable IGF-I and bone mass, or risk of fractures, it is not clear that it is causal. Caution must be undertaken in deciphering the results of a low, normal, or high IGF-I in relation to osteoporosis. Further studies should help define more clearly the possible pathogenic relationship between IGF-I and bone mass.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Ahren B.
        • Iarsson H.
        • Wilhemsson C.
        • et al.
        Regulation of circulating leptin in humans.
        Endocrine. 1997; 7: 1-8
        • Andersen G.H.
        • Francis R.M.
        • Silly P.L.
        • et al.
        Sex hormones and osteopenia in men.
        Calcif Tissue Int. 1998; 62: 185-188
        • Baserga R.
        • Resnicoff M.
        • Dews M.
        The IGF-I receptor and cancer. 1997; 7: 99-103
        • Bauer D.C.
        • Rosen C.
        • Cauley J.
        • et al.
        Low serum IGF-1 but not IGFBP-3 predicts hip and spine fracture: The study of osteoporotic fracture.
        J Bone Miner Res. 1998; 12: s561
        • Bing-you R.G.
        • Denis M.G.
        • Rosen C.J.
        Low bone mineral density in adults with previous hypothalamic pituitary tumors.
        Calcif Tissue Int. 1993; 52: 183-187
        • Binoux M.
        IGF-binding protein-3 and acid-labile subunit: What is the pecking order?.
        Eur J Endocrinol. 1997; 137: 605-609
        • Blum W.F.
        • Alberttson K.
        • Roseberg S.
        • et al.
        Serum levels of IGF-I and IGFBP-3 reflect spontaneous GH secretion.
        J Clin Endocrinol Metab. 1993; 76: 1610-1630
        • Burich H.B.
        • Wolf L.
        • Budde R.
        • et al.
        Androstenedione metabolism in cultured human osteoblast like cells.
        J Clin Endocrinol Metab. 1992; 75: 101-105
        • Campbell P.G.
        • Novak T.F.
        • Yanoscik T.B.
        • et al.
        Involvement of the plasmin system in dissociation of IGFBP complex.
        Endocrinology. 1992; 130: 1401-1402
        • Canalis E.
        • Centrella M.
        • Bach W.
        • et al.
        IGF-I mediates selective anabolic effects of PTH in bone cell cultures.
        J Clin Invest. 1989; 63: 60-65
        • Canalis E.
        • McCarthy T.L.
        • Centrella M.
        Growth factors and bone remodeling.
        J Clin Invest. 1988; 81: 277-281
        • Carani C.
        • Quirk C.
        • Sinai M.
        • et al.
        Effect of testosterone and estradiol in a male with aromatasedeficiency.
        N Engl J Med. 1997; 337: 91-95
        • Chan K.
        • Spencer E.M.
        General aspects of the IGFBPs.
        Endocrine. 1997; 7: 95-97
        • Clemmons D.R.
        • Elgin R.G.
        • Han V.K.M.
        • et al.
        Cultured fibroblast monolayers secrete a protein that alters the cellular binding of somatomedin C/IGF I.
        J Clin Invest. 1986; 77: 1548-1556
        • Commuzie G.
        • Blangero J.
        • Mahaney M.C.
        • et al.
        Genetic and environmental correlates among hormone levels and means of body fat accumulation and topography.
        J Clin Endocrinol Metab. 1996; 81: 597-600
        • Conover C.A.
        The role of IGFs and IGFBPs in bone cell biology.
        in: Bilezikian J.P. Raisz L.R. Rodan G. Principles of Bone Biology. Academic Press, San Diego, CA1996: 607-618
        • Cook F.
        • Rosen C.J.
        • Vereault D.
        • et al.
        Major changes in the circulatory IGF regulatory system after hip fracture surgery.
        J Bone Miner Res. 1996; 11: S327
        • Coverley J.A.
        • Baxter R.C.
        Phophorylation of IGFBPs.
        Mol Cell Endocrinol. 1997; 128: 1-5
        • Davis P.Y.
        • Frazier C.R.
        • Shapiro J.R.
        • et al.
        Age-related changes in effects of IGF-I on human osteoblast like cells.
        Biochem J. 1997; 324: 753-760
        • DePugola G.
        • Lespite L.
        • Grizzulli V.A.
        • et al.
        IGF-I and DHEA-S in obese females.
        Int J Obes Relat Metab Disord. 1993; 11: 481-483
        • Donahue L.R.
        • Hunter S.J.
        • Sherblom A.P.
        • et al.
        Age-related changes in serum IGFBPs in women.
        J Clin Endocrinol Metab. 1990; 71: 575-579
        • Ensrud K.E.
        • Cauley J.
        • Lipschutz R.
        • et al.
        Weight change and fractures in older women. Study of osteoporotic fracture.
        Arch Intern Med. 1997; 157: 857-863

      23. Estivarez CE, Ziegler TR: Nutrition and the IGF system. Endocrine 65-71, 1997

        • Fowlkes J.
        • Enghild J.
        • Suzuki K.
        • et al.
        Matrix metalloproeinases degrade IGFBP-3 in dermal fibroblast cultures.
        J Biol Chem. 1994; 269: 25742-25746
        • Gelato M.C.
        • Frost R.A.
        IGFBP-3 Functional and structural implications in aging and wasting syndromes.
        Endocrine. 1977; 7: 81-85
        • Greendale G.A.
        • Deistein S.
        • Barrett Connor E.
        Endogenous sex steroids and bone mineral density in older men and women.
        J Bone Miner Res. 1997; 12: 1833-1843
        • Grinspoon S.K.
        • Baum H.B.A.
        • Peterson S.
        • et al.
        Effects of rhIGF-I administration on bone turnover during short-term fasting.
        J Clin Invest. 1995; 96: 900-905
        • Grogean T.
        • Vereault D.
        • Millard P.S.
        • et al.
        A comparative analysis of methods to measure IGF-I in human serum.
        Endocr Metab. 1997; 4: 109-114
        • Harrela M.
        • Koistinen H.
        • Kaprio J.
        • et al.
        Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3.
        J Clin Invest. 1996; 98: 2612-2615
        • Hayden J.
        • Mohan S.
        • Baylink D.J.
        The IGF system and the coupling of formation to resorption.
        Bone. 1995; 17: 93-98S
        • Ho K.Y.
        • Evans W.S.
        • Blizzard R.
        • et al.
        Effects of sex and age on twenty four hour profiles of GH secretion in men.
        J Clin Endocrinol Metab. 1987; 64: 51-58
        • Hobbs C.J.
        • Plymate S.R.
        • Rosen C.J.
        • et al.
        Testosterone administration increases IGF-I in normal men.
        J Clin Endocrinol Metab. 1993; 77: 776-780
        • Hoffman A.R.
        • Lieberman S.A.
        • Butterfield G.
        • et al.
        Functional consequences of the somatopause and its treatment.
        Endocrine. 1997; 7: 73-76
        • Jones J.
        • Clemmons D.R.
        IGFs and their binding proteins.
        Endocr Rev. 1995; 16: 3-32
        • Jones J.
        • Gockerman A.
        • Busby J.W.
        • et al.
        Extracellular matrix contains IGFBP-5: Potentiation of the effects of IGF-I.
        J Cell Biol. 1993; 121: 679-687
        • Kanzaki S.
        • Hilliker S.
        • Baylink D.J.
        • et al.
        Evidence that human bone cells in culture produce IGFBP-4 and IGFBP-5 proteases.
        Endocrinology. 1994; 134: 383-392
        • Kao P.C.
        • Matheny A.P.
        • Lang C.A.
        IGF-I comparisons in healthy twin children.
        J Clin Endocrinol Metab. 1994; 78: 310-312
        • Koperak C.
        • Fittsimmons R.
        • Stein D.
        • et al.
        Studies of the mechanisms by which androgens enhance mitogenesis and differentiation of bone cells.
        J Clin Endocrinol Metab. 1990; 71: 329-337
        • Kurland E.S.
        • Chan F.
        • Vereault D.
        • et al.
        Growth hormone IGF-I axis in men with idiopathic osteoporosis and reduced circulating levels of IGF-I.
        J Bone Miner Res. 1996; 11: S323
        • Kurland E.
        • Rackoff P.J.
        • Adler R.A.
        • et al.
        Heritability of Serum IGF-I and its Relationship to Bone Density. The Endocrine Society, New Orleans, LA1998
        • Kurland E.S.
        • Rosen C.J.
        • Cosman F.
        • et al.
        IGF-I in men with idiopathic osteoporosis.
        J Clin Endocrinol Metab. 1997; 82: 2799-2805
        • Labrie F.
        • Belanger A.
        • Cusan L.
        • et al.
        Physiological changes in DHEA are not reflected by serum levels of active androgens and estrogens but their metabolites.
        J Clin Endocrinol Metab. 1997; 82: 2403-2409
        • Langlois J.A.
        • Rosen C.J.
        • Visser M.
        • et al.
        Association between insulin-like growth factor 1 and bone mineral density in older women and men.
        The Framingham Heart Study. 1998; 83: 4257-4262
        • LeBoff M.S.
        • Rosen C.J.
        • Glowacki J.
        Changes in growth factors and cytokines in postmenopausal women.
        J Bone Miner Res. 1995; 10: 241-261
        • LeRoith D.
        • Parrizas M.
        • Blakesley V.A.
        IGF-I receptor and apoptosis.
        Endocrine. 1997; 7: 103-105
        • LeRoith D.
        • Werner H.
        • Butner-Johnson D.
        • et al.
        Molecular and cellular aspects of the IGF-I receptor.
        Endocr Rev. 1995; 16: 143-153
        • Linkhart T.A.
        • Mohan S.
        PTH stimulates release of IGF-I and IGF-II from neonatal mouse calvariae.
        Endocrinology. 1989; 125: 1484-1491
        • Ludwig T.
        • Eggenschwiler J.
        • Fisher P.
        • et al.
        Mouse mutants lacking the type 2 IGF receptor (IGF2R) are rescued from perinatal lethality in Igf2 and Igflr null backgrounds.
        Dev Biol. 1996; 177: 517-535
        • Martha P.M.
        • Gooman K.M.
        • Blizzard R.M.
        • et al.
        Endogenous GH secretion and clearance in normal boys as determined by deconvolution analysis.
        J Clin Endocrinol Metab. 1992; 74: 336-344
        • McCarthy T.L.
        • Centrella M.
        • Canalis E.
        PTH enhances the transcript and polypeptide levels of IGF-I in osteoblast enriched cultures from fetal rate calvariae.
        Endocrinology. 1989; 124: 1247-1253
        • McCarthy T.L.
        • Centrella M.
        • Canalis E.
        Regulatory effects of IGF-I and IGF-II on bone collagen synthesis in rat calvarial cells.
        Endocrinology. 1989; 124: 301-308
        • McCarthy T.L.
        • Ji C.
        • Slu H.
        • et al.
        17 Beta estradiol suppresses cyclic AMP induced IGF-I gene transcription in primary rat osteoblast cultures.
        J Biol Chem. 1997; 272: 18132-18139

      53. Milne M, Kang M, Wuail JM et al: Thyroid hormone excess increases IGF-I transcripts in bone marrow cell cultures: Divergent effects on vertebral and femoral cell cultures. Endocrinology, in press

        • Mohan S.
        IGF binding proteins in bone cell regulation.
        Growth Regulation. 1993; 3: 65-68
        • Mohan S.
        • Baylink D.J.
        Autocrine and paracrine aspects of bone metabolism.
        Growth Gen Horm. 1990; 6: 1-9
        • Mohan S.
        • Baylink D.J.
        Serum IGFBP-4 and IGFBP-5 in aging and age-associated diseases.
        Endocrine. 1997; 7: 87-91
        • Mohan S.
        • Farley J.R.
        • Baylink D.J.
        Age-related changes in IGFBP-4 and IGFBP-5 in human serum and bone: Implications for bone loss with aging.
        Prog Growth Factor Res. 1995; 6: 465-473
        • Morales A.J.
        • Nolan J.J.
        • Lukes C.C.
        • et al.
        Effects of replacement doses of DHEA in men and women.
        J Clin Endocrinol Metab. 1994; 78: 1360-1361
        • Myers M.G.
        • Sur X.J.
        • Christian B.
        • et al.
        IRS-1 is a common element in insulin and IGF-I signaling to PI-3’kinase.
        Endocrinology. 1993; 132: 1421-1427
        • Oh Y.
        IGFBPs and neoplastic models: New concepts for roles of IGFBPs in regulation of cancer cell growth.
        Endocrine. 1997; 7: 115-117
        • Poehlman E.T.
        • Toth M.J.
        • Ades P.A.
        • et al.
        Menopause associated changes in plasma lipids insulin-like growth factor-I and blood pressure: A longitudinal study.
        Eur J Clin Invest. 1997; 27: 322-326
        • Rajaram S.
        • Baylink D.J.
        • Mohan S.
        IGFBPs in serum and other biological fluids.
        Endocr Rev. 1997; 18: 801-831
        • Ravn P.
        • Overgaard K.
        • Spencer E.M.
        • et al.
        IGF-I and IGF-II in healthy females.
        Eur J Endocrinol. 1995; 132: 313-319
        • Reed B.Y.
        • Zerwekh J.E.
        • Sakhaee K.
        • et al.
        Serum IGF 1 is low and correlated with osteoblastic surface in idiopathic osteoporosis.
        J Bone Miner Res. 1995; 10: 1214-1218
        • Rosen C.J.
        • Conover C.
        Growth hormone/insulin-like growth factor-I axis in aging: A summary of a National Institutes of Health aging-sponsored symposium.
        J Clin Endocrinol Metab. 1997; 82: 3919-3922
        • Rosen C.J.
        • Dimai H.P.
        • Vereault D.
        • et al.
        Circulating and skeletal insulin-like growth factor-1 (IGF-I) concentrations in two inbred strains of mice with different bone mineral densities.
        Bone. 1997; 217: 22-27
        • Rosen C.J.
        • Donahue L.R.
        • Hunter S.J.
        IGFs and bone: The osteoporosis connection.
        Proc Soc Exp Biol Med. 1994; 206: 83-102
        • Rosen C.J.
        • Kurland E.S.
        • Vereault D.
        • et al.
        Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-1 gene: Implications for genetic studies of bone mineral density.
        J Clin Endocrinol Metab. 1998; 83: 2286-2290
        • Rosen C.J.
        • Vereault D.
        • Steffens C.
        • et al.
        Effect of age and estrogen status on the skeletal IGF regulatory system.
        Endocrine. 1997; 7: 77-80
        • Rudman D.
        • Feller A.G.
        • Nelgrag H.S.
        Effect of human GH in men over age 60.
        N Engl J Med. 1990; 323: 52-60
        • Salmon W.D.
        • Daughaday W.H.
        A hormonally controlled serum factor which stimulates sulphate incorporation by cartilage in vitro.
        J Lab Clin Med. 1957; 49: 825-836
        • Shewmon D.A.
        • Stock J.L.
        • Rosen C.J.
        • et al.
        Effects of estrogen and tamoxifen on Lp(a) and IGF-I in healthy postmenopausal women.
        Arterioscler Thromb Vase Biol. 1995; 14: 1562-1586
        • Slootwigh M.C.
        Growth hormone and bone.
        Horm Metab Res. 1998; 25: 335-345
        • Slowik D.M.
        • Rosenthal D.I.
        • Doppelt S.H.
        • et al.
        Restoration of spinal bone mass in osteoporotic males by treatment with human PTH and 1,25 dihydroxy vitamin D.
        J Bone Miner Res. 1986; 1: 377-388
        • Smith E.P.
        • Boyd F.
        • Frank G.
        • et al.
        Estrogen resistance caused by a mutation in the ER gene in a man.
        N Engl J Med. 1994; 331: 1056-1061
        • Thraillkill K.
        • Quarles L.D.
        • Nagase H.
        • et al.
        Characterization of IGFBP-5 degrading proteases produced throughout murine osteoblast differentiation.
        Endocrinology. 1995; 136: 3527-3533
        • Toogood A.A.
        • O’Neil P.A.
        • Shalet S.A.
        Beyond the somatopause: GHD in adults over age 60.
        J Clin Endocrinol Metab. 1996; 81: 460-463
        • Tremollieres F.A.
        • Strong D.D.
        • Baylin D.
        • et al.
        Progesterone and promogesterone stimulates human bone cell proliferation and IGF-II production.
        Acta Endocrinol. 1992; 126: 329-337
        • Twigg S.M.
        • Baxter R.C.
        IGF binding protein 5 forms and alternative ternary complex with IGFs and the acid-labile subunit.
        J Biol Chem. 1998; 273: 6074-6079
        • Veldhuis J.D.
        • Iranmanesh A.
        • Weltman A.
        Elements in the pathophysiology of diminished GH secretion in aging humans.
        Endocrine. 1997; 7: 41M8
        • Veldhuis J.D.
        • Kerr T.Y.
        • South J.
        • et al.
        Differential impact of age, sex steroids and obesity on basal vs pulsatile GH secretion.
        J Clin Endocrinol Metab. 1995; 82: 3209-3222
        • Zapf J.
        • Froesch E.
        IGFs/Somatomedins: Structure, secretion, biological actions and physiological roles.
        Horm Res. 1986; 24: 121-130
        • Zapf J.
        • Schmid C.
        • Froesche E.R.
        Biological and immunological properties of IGF-I and IGF-II.
        Clin Endocrinol Metab. 1984; 13: 7-12

      Article info

      Identification

      DOI: https://doi.org/10.1016/S0272-2712(18)30055-6

      Copyright

      © 2000 Elsevier Inc. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX